{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5"],"submitter":["Yeung SHM"],"pubmed_abstract":["<h4>Background</h4>Strongyloidiasis is a common infection in Canadian migrants that can cause life-threatening hyperinfection in immunosuppressed hosts. We designed and implemented a safety tool to guide management of patients with <i>Strongyloides</i> in order to prevent adverse outcomes. Methods: Patients treated at our centre for strongyloidiasis from January 1, 2013 to December 31, 2015 were identified through our ivermectin access log. Patients were categorized into pre-implementation and post-implementation groups. A retrospective chart review for predefined variables was conducted.<h4>Results</h4>Of 37 patients with strongyloidiasis, 26 were in the pre-implementation group and 11 were in the post-implementation group. Documented seroreversion (positive to negative) occurred in 42.1%"],"journal":["Tropical diseases, travel medicine and vaccines"],"pagination":["3"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6448213"],"repository":["biostudies-literature"],"pubmed_title":["Implementation and evaluation of a quality and safety tool for ambulatory strongyloidiasis patients at high risk of adverse outcome."],"pmcid":["PMC6448213"],"pubmed_authors":["Yeung SHM","Boggild AK","Mourad O","Klowak S","Klowak M","Showler AJ"],"additional_accession":[]},"is_claimable":false,"name":"Implementation and evaluation of a quality and safety tool for ambulatory strongyloidiasis patients at high risk of adverse outcome.","description":"<h4>Background</h4>Strongyloidiasis is a common infection in Canadian migrants that can cause life-threatening hyperinfection in immunosuppressed hosts. We designed and implemented a safety tool to guide management of patients with <i>Strongyloides</i> in order to prevent adverse outcomes. Methods: Patients treated at our centre for strongyloidiasis from January 1, 2013 to December 31, 2015 were identified through our ivermectin access log. Patients were categorized into pre-implementation and post-implementation groups. A retrospective chart review for predefined variables was conducted.<h4>Results</h4>Of 37 patients with strongyloidiasis, 26 were in the pre-implementation group and 11 were in the post-implementation group. Documented seroreversion (positive to negative) occurred in 42.1%","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019","modification":"2026-07-17T00:12:58.38Z","creation":"2019-06-06T21:06:05Z"},"accession":"S-EPMC6448213","cross_references":{"pubmed":["30988956"],"doi":["10.1186/s40794-019-0080-1"]}}